Kailera's Oral GLP-1 KAI-7535 Achieves Up to 10.9% Weight Loss in Phase 3 Obesity Trial
KLRA sits 30% above its 52-week low of $18.5.
Summary
Kailera Therapeutics announced strong positive topline Phase 3 data for its oral GLP-1 receptor agonist, KAI-7535, in both obesity and Type 2 Diabetes, with the drug meeting the main goal of late-stage trials in China. In the HARBOR-1 obesity trial, patients achieved a mean weight loss of up to 10.9% from baseline at Week 44, significantly outperforming placebo. This success provides concrete validation for a key asset in the highly competitive GLP-1 market, following the company's recent IPO and general positive pipeline updates. The efficacy demonstrated is competitive for an oral GLP-1, positioning KAI-7535 as a potential significant player. Kailera is also conducting a global Phase 2 trial for KAI-7535, with data expected in 2027.
At the time of this announcement, KLRA was trading at $23.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $18.50 to $28.23. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.